StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Puma Biotechnology's operating cash flow for the twelve months ending Jun 30, 2026 was $41.15M, down 7.2% year over year. For fiscal 2025 it was $41.80M, up 7.4% from the year before. The highest annual figure on record is $41.80M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.80M+7.4%
FY2024Dec 31, 2024$38.92M+44.1%
FY2023Dec 31, 2023$27.01M–
FY2022Dec 31, 2022-$15.83M-176.6%
FY2021Dec 31, 2021$20.65M+2571.4%
FY2020Dec 31, 2020$773.00K-96.5%
FY2019Dec 31, 2019$22.38M–
FY2018Dec 31, 2018-$24.11M–
FY2017Dec 31, 2017-$172.47M–
FY2016Dec 31, 2016-$141.69M–
FY2015Dec 31, 2015-$154.47M–
FY2014Dec 31, 2014-$77.20M–
FY2013Dec 31, 2013-$55.05M–
FY2012Dec 31, 2012-$44.01M–
FY2011Dec 31, 2011-$1.82M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.62M-88.5%
Q1 FY2026Mar 31, 2026$15.42M+326.8%
Q4 FY2025Dec 31, 2025$14.42M-7.6%
Q3 FY2025Sep 30, 2025$9.69M-12.2%
Q2 FY2025Jun 30, 2025$14.08M+1271.2%
Q1 FY2025Mar 31, 2025$3.61M-67.9%
Q4 FY2024Dec 31, 2024$15.61M+49.3%
Q3 FY2024Sep 30, 2024$11.04M+4.0%
Q2 FY2024Jun 30, 2024$1.03M-68.8%
Q1 FY2024Mar 31, 2024$11.25M+325.5%
Q4 FY2023Dec 31, 2023$10.46M+36.1%
Q3 FY2023Sep 30, 2023$10.62M-38.5%
Q2 FY2023Jun 30, 2023$3.30M–
Q1 FY2023Mar 31, 2023$2.64M–
Q4 FY2022Dec 31, 2022$7.68M–
Q3 FY2022Sep 30, 2022$17.26M+64.4%
Q2 FY2022Jun 30, 2022-$13.87M–
Q1 FY2022Mar 31, 2022-$26.90M-271.7%
Q4 FY2021Dec 31, 2021-$5.44M–
Q3 FY2021Sep 30, 2021$10.50M+510.3%
Q2 FY2021Jun 30, 2021-$74.00K-100.5%
Q1 FY2021Mar 31, 2021$15.66M–
Q4 FY2020Dec 31, 2020-$5.64M-459.8%
Q3 FY2020Sep 30, 2020$1.72M–
Q2 FY2020Jun 30, 2020$16.23M-63.3%
Q1 FY2020Mar 31, 2020-$11.54M–
Q4 FY2019Dec 31, 2019$1.57M-77.8%
Q3 FY2019Sep 30, 2019-$7.31M–
Q2 FY2019Jun 30, 2019$44.25M–
Q1 FY2019Mar 31, 2019-$16.13M–
Q4 FY2018Dec 31, 2018$7.05M–
Q3 FY2018Sep 30, 2018-$7.26M–
Q2 FY2018Jun 30, 2018-$17.64M–
Q1 FY2018Mar 31, 2018-$6.25M–
Q4 FY2017Dec 31, 2017-$35.61M–
Q3 FY2017Sep 30, 2017-$54.91M–
Q2 FY2017Jun 30, 2017-$45.91M–
Q1 FY2017Mar 31, 2017-$36.04M–
Q4 FY2016Dec 31, 2016-$40.96M–
Q3 FY2016Sep 30, 2016-$34.89M–

More Puma Biotechnology figures

See a number that looks wrong?